Anti-Ageing Drugs Market Research Report-Forecast till 2030

Anti-Ageing Drugs Market Information: by Drug Class (serums and supplements, antioxidants and enzymes, stem cells, drugs) by Applications (skin and hair, skeletal and muscles, age related disorders, others) - Global forecast till 2030

ID: MRFR/Pharma/2408-CR | February 2021 | Region: Global | 260 Pages         

Anti Ageing Drugs Market Speak to Analyst Request a Free Sample

Anti-Ageing Drugs Market

Anti-ageing drugs market is expected grow USD 90.20 Billion at a CAGR 7.10% during the forecast 2022 - 2030

By Drug Class Serums and supplements antioxidants and enzymes stem cells drugs
By Applications Skin and hair skeletal and muscles age related disorders others
Key Players
Companies Profiled   Nu Skin - USA   BIOTIME Inc - USA   Elysium Health Inc - France   La Roche-Posay - France   DermaFix - USA   L‚ÄôOreal - USA
Market Driving Forces   Increase in the global geriatric population
Request a Free Sample

Anti-Ageing Drugs Market Overview

The CAGR for the anti-ageing drugs market is expected to be 7.10% until the end of 2030. The market is expected to be worth USD 90.20 billion dollars during the forecat period 2022-2030. 

anti-ageing drugs¬†come in many forms. One of these is¬†anti-ageing¬†pills.¬†They promise to be to the 21st century what the ‚Äėfountain of youth‚Äô was to the 16th. Their goal is to help people live longer and healthier lives. This is accomplished by slowing down and even reversing the aging process.¬†

COVID-19 analysis of Anti-Ageing Drugs Market

COVID-19 disrupted all industries around the world when it first appeared on the global scene in March of 2020. Many nations responded to this damaging and potentially deadly virus by initiating temporary quarantines and indefinite lockdowns. 

The anti-ageing drugs market was adversely affected. One of the keyways was in procurement of the materials necessary for research and development and for anti-ageing drug development. These raw materials became rare. Their prices also increased dramatically. This caused a slowdown in anti-ageing drugs sales because manufacturers were forced to pass the higher costs onto the end consumer in the form of higher retail prices. 

Market dynamics


The world is graying rapidly. China’s one child per family policy which has been instituted for almost four decades is a major contributing factor. So is the fact that almost all Western nations have large baby boom populations that were born immediately after World War II. 

The World Health Organization (WHO) also has some interesting statistics regarding the dramatic and projected increase in the global geriatric population in the second half of the 21st century. The global elderly population is expected to increase from 12% of the total population in 2015 to 22% of the global population by 2050. 

It is also a WHO estimate that there will be many more people aged 60 and above by 2050 than there are people aged 5 and younger. Four out of every five of these people are expected to be living in developing and third world nations. 


The strong and rapid growth in the global elderly population is creating lots of opportunities in terms of anti-ageing drug development. More and more elderly people want to look and feel as young as possible. Much of this desire is driven by the media which never tires of presenting elderly celebrities in a new and younger light. Since these celebrities rely heavily on anti-aging drugs and anti-ageing pills, more and more elderly around the world want to use these drugs. 


Many key people and players in society are sceptical about the claims of these anti-ageing drugs. They claim that these drugs are overhyped and may even be unsafe to use. Many people are also (rightly) concerned about the safety and long-term effects of using these drugs since many of these have not been approved by the Food and Drug Administration (FDA) or other national food and drug regulatory agencies either in America or other nations. 

Many nations are starting to wake up to the potential dangers of these drugs. That is why they are starting to regulate these drugs heavily and strictly. 


Since the anti-ageing drugs market is largely unregulated, anyone can come with drugs that claim to reverse the aging process and make fantastic claims and promises. In fact, the anti-ageing drugs market is indeed full of quacks and charlatans. Unfortunately, many of these people care little about the health and safety of the end customer. They also are pedaling drugs with unknown and potentially dangerous short and long-term side effects. 

Technology analysis

The recent and intensive investments in research and development by companies in the anti-ageing drugs industry is reaping huge dividends. These are in the form of a new generation of more powerful and effective anti-ageing drugs market. The market is lucrative since the end consumer is often willing and able to pay a premium price for these drugs.

BIOTIME Inc recently introduced its PEA supplement on the global anti-ageing drugs market. It adds to the PEA that the human body produces. The result is less of the pain and aches/suffering that older people tend to experience. 

Anti-Ageing Drugs Market Segment overview

By Drug Class

The anti-ageing drugs market is divided into many segments. These are serums and supplements, antioxidants and enzymes, and stem cells and (anti-aging) drugs. 

By Application

The anti-ageing drugs market is divided to many segments in terms of application:

  • Skin and hair

  • Bones and muscles

  • Age related diseases and disorders and others¬†

Anti-Ageing Drugs Market Regional analysis

According to many anti-ageing drugs market reports the North American region commands the greatest anti-ageing drugs market size. America commands the lion’s share of this market size. There are many reasons for this. They are the fact that gross and per-capita incomes are the highest in America. The fact that America has a large and rapidly increasing elderly population is another key factor. This elderly population is also among the wealthiest demographic segment in America. This is another key factor.

The anti-ageing drug market was worth USD 42.470.5 million in 2016 and that was just in America! 

The European union has the second largest anti-ageing drugs market size. This is largely because almost all European nations have nationalized and/or socialized universal health care. The governments can therefore afford to spend lavishly on the research and development that companies in the anti-ageing drug industry need to thrive. Another key contributing factor is the fact that European media promotes the importance of youthfulness. It also emphasizes anti-ageing drugs and their many benefits. 

The Asia-Pacific region is expected to experience the largest growth in the anti-ageing drugs market. At present, this is largely because Japan has a large elderly population. This is expected to grow dramatically in the next few years. The Japanese elderly also have relatively high discretionary incomes and purchasing power. 

Demand for anti-ageing drugs is expected to grow rapidly in China in the next few years. Demographics and the one-child-per-family policy are the key culprits. Disposable income for the elderly is rising fast in China, but not as fast as it is in developed nations. 

India is expected to see an increase in demand for these drugs after 10-15 years. The reason why is because birth rates are dropping dramatically in this nation. Disposable income and purchasing power are also rising rapidly in India. In fact, the CAGR for anti-aging drugs in this region is expected to be 15.3% until the end of 2023. 

The Middle East North Africa (MENA) and the rest of the world region is expected to see limited growth. The main constraining factors are abject poverty, corruption, low economic growth, unstable political conditions, and bad healthcare that is not subjected to regular infusions of money. 

Competitive landscape

The anti-ageing drugs market is very competitive. Though there are significant barriers to entry, many large companies already call this market home. This will help them produce newer drugs that are more effective and more expensive. They are also engaging in joint-ventures and mergers and acquisitions. This will help them enter new markets with ease! 

BIOTIME Inc is a major player in the anti-ageing drugs industry. It is surviving by constantly introducing new products to the market. These have high price points. 

List of companies

  • Nu Skin - USA


  • Elysium Health Inc - France

  • La Roche-Posay - France

  • DermaFix - USA

  • L‚ÄôOreal - USA¬†

Recent developments

  • Many¬†anti-ageing¬†drug companies are introducing a new generation of powerful¬†anti-aging drugs¬†to market. These are called senolytics.

  • Wellness companies are starting to do research and development to develop and market these drugs.

  • Some startups offer older employees blood transfusions from young people. The objective is to try to make the older employees look and feel younger.

  • Research and development are propping up the biogerontology industry.

  • More and more companies are educating people about the aging process and how to reverse this.¬†

Report overview

The anti-ageing drugs market is experiencing a strong CAGR of over 7.10% a year. This is expected to continue at least until the end of 2030. Many companies are investing heavily in research and development to try to bring a new generation of potent and pricier anti-aging drugs to market.

Report Scope:

Report Attribute/Metric Details
  Market Size   USD 90.20 billion
  CAGR   7.10%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Product, Application, Region
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Nu Skin - USA, BIOTIME Inc - USA, Elysium Health Inc - France, La Roche-Posay - France, DermaFix - USA, L‚ÄôOreal - USA
  Key Market Opportunities   The strong and rapid growth in the global elderly population is creating lots of opportunities in terms of anti-ageing drug development.
  Key Market Drivers

  • The world is graying rapidly. China‚Äôs one child per family policy which has been instituted for almost four decades is a major contributing factor.
  • The World Health Organization (WHO) also has some interesting statistics regarding the dramatic and projected increase in the global geriatric population

  • Speak to Analyst Ask for Customization